Investor Presentaiton
Our Journey: Three decades of delivering on promises
Formative years with focus on APIs
Global footprint, Established
dominance in Core APIs + PFIs,
Entered Finished dosages space
Expanding into complex
generics + Strengthening
market penetration in
regulated markets
Moving towards
complex technology
1984 1990 1991 1993 1995 2001 2002 2003 2005 2008 2010 2013 2014 2014 2015 2016 2019 2020 2022 2022
Established
first PFI
facility at
Jeedimetla
Incorporated
Granules India
Private Limited
Opened 2nd
API facility in
Jeedimetla
Granules formed as
Triton Labs to
produce Paracetamol
API at Bonthapally
Listed on
the BSE
Entered the
Finished
dosage
segment
Merger of
Triton with
Granules
New
Paracetamol
plant at
Bonthapally
Listed on the
Hyderabad
Stock Exchange
Set up a large-volume
PFI facility in Gagillapur
and a wholly owned
subsidiary Granules
USA for marketing in
the US
Received
USFDA
Acquired API
manufacturing
facility in Vizag
to further
strengthen the
API portfolio
Established
15,000 sqft
R&D facility
in Hyderabad
approval for its
first ANDA
Laid down the
foundation for
its Oncology
OSD Plant in
Vizag
Entered OTC business
in US through
Granules Consumer
Healthcare
Incorporated Granules
Pharmaceutical Inc in
the US to focus on
formulations in the
US
Acquired
Sajjla
Bio Labs to
augment
Biotechnology
R&D
Laid foundation
for the largest
single
manufacturing site
for MUPS facility
Commenced sale
of Rx Products in
the US under the
GPI Label
Completed share
buy-back worth
Rs.311 Cr
(including taxes
and transaction
cost)
9View entire presentation